Affiliate programs for GLP-1 drugs are run by telehealth brands, not by the drug makers. We found no public affiliate program on the Novo Nordisk or Eli Lilly sites as of November 1, 2026. Both sell direct, through NovoCare Pharmacy and LillyDirect. You earn by promoting the telehealth programs that prescribe Wegovy, Zepbound, Foundayo or compounded semaglutide and tirzepatide.
Which GLP-1 drugs an affiliate can promote, and through whom
Each GLP-1 medication reaches the buyer through a different seller, and that seller decides whether an affiliate gets paid. The table maps each drug on November 1, 2026.
| Medication | Maker | Maker’s own channel | Maker affiliate program | Where an affiliate gets paid |
|---|---|---|---|---|
| Wegovy pen and pill (semaglutide) | Novo Nordisk | NovoCare Pharmacy | None found | Telehealth brands that prescribe it |
| Ozempic pen and pill (semaglutide) | Novo Nordisk | NovoCare Pharmacy | None found | Telehealth brands, but the label is type 2 diabetes (see below) |
| Zepbound vial and pen (tirzepatide) | Eli Lilly | LillyDirect | None found | Telehealth brands that prescribe it |
| Foundayo pill (orforglipron) | Eli Lilly | LillyDirect | None found | Telehealth brands that prescribe it |
| Mounjaro (tirzepatide) | Eli Lilly | LillyDirect | None found | Same label issue as Ozempic |
| Compounded semaglutide or tirzepatide | 503A compounding pharmacies | None | n/a | Telehealth brand affiliate programs, where most published GLP-1 payouts sit |
“Wegovy affiliate program” and “Ozempic affiliate program” searches look for something the makers don’t run. A semaglutide affiliate program or a tirzepatide affiliate program is always a telehealth brand’s program, and the drug is one item on that brand’s menu. For the program side of that, see our GLP-1 affiliate commissions guide.
How Novo Nordisk and Eli Lilly sell GLP-1 drugs direct
Novo Nordisk and Eli Lilly sell their GLP-1 drugs to cash-pay buyers through their own pharmacy channels, and send people who need a prescription to independent telehealth providers. Neither list is an affiliate program.
NovoCare Pharmacy is Novo Nordisk’s channel. Its home delivery page lists Wegovy pill and pen and Ozempic pill and pen at self-pay prices. Its Find care page lists telehealth providers including 9amHealth, eMed, FormHealth, Hims & Hers, Knownwell, LifeMD, Ro, Sesame and WeightWatchers, and states: “Novo Nordisk operates independently and does not endorse these health care providers or organizations.”
LillyDirect is Eli Lilly’s channel and sells Zepbound, Foundayo and Mounjaro. Its homepage tells buyers to “Ask your doctor to send your prescription to LillyDirect Pharmacy. If you need a doctor, we’ll help you connect with care.” Lilly’s obesity telehealth page lists Counsel Health, General Medicine, Sesame, WeightWatchers and knownwell, with the line “Lilly does not endorse or recommend these health care providers.”
What this means for an affiliate:
- The makers’ channels have no tracking link for you. The provider lists carry the makers’ own UTM tags, not affiliate IDs.
- The brands on those lists are where branded traffic converts. WeightWatchers, which appears on both lists, has a public affiliate page (checked November 1, 2026). It pays “a base commission of $10 for every qualifying subscription,” through Impact, and the page doesn’t say whether GLP-1 memberships qualify.
- Branded programs that aren’t public are reached through a network or the brand’s partner team. Our guide to finding GLP-1 brand affiliate programs covers where to look.
What changes per drug for a GLP-1 affiliate
The drug on the landing page changes three things for a GLP-1 affiliate: the claims you can make, the price the visitor sees, and often the payout.
Wegovy and Zepbound: branded, labeled for weight
Wegovy and Zepbound are the branded injections an affiliate can name on a weight-loss page, because their labels cover weight. Wegovy.com says Wegovy is used to “help adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.” LillyDirect says Zepbound “may help adults with obesity to lose weight and keep it off along with a reduced-calorie diet and increased physical activity.”
Price points the visitor may already know, from the makers’ own pages on November 1, 2026:
- NovoCare: Wegovy pen $199 a month for a new buyer’s first 2 fills of the starting doses, through December 31, 2026, then $349 a month ($399 for Wegovy HD).
- LillyDirect: Zepbound from $299 a month at the starting dose, $399 and $449 at higher doses, with the $449 price tied to refilling “within 45 days.”
A telehealth brand that sells these drugs usually adds a membership or visit fee on top. Your copy should quote the brand’s price, not the maker’s.
Wegovy pill and Foundayo: the oral options
The oral GLP-1 options give affiliates a no-injection angle with lower entry prices. Novo Nordisk announced FDA approval of the Wegovy pill on December 22, 2025, “the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight” management. Lilly sells Foundayo (orforglipron), its oral GLP-1, through LillyDirect; FDA approved it on April 1, 2026, and Lilly announced US availability on April 9, 2026.
- NovoCare: Wegovy pill $149 a month at the lowest-priced dose, $199 and $299 at higher doses.
- LillyDirect: Foundayo “Starting at $149/month,” with two doses “temporarily reduced through December 31, 2026,” then $199 and $299 at higher doses.
Compounded oral products exist too. Henry Meds’ programs page lists “compounded orally dissolving” semaglutide and tirzepatide tablets. Keep the two apart in your copy: a branded pill and a compounded tablet are different products.
Ozempic and Mounjaro: diabetes labels
Ozempic and Mounjaro are well-known GLP-1 names, and both are labeled for type 2 diabetes. Ozempic.com titles itself “GLP-1 RA for Type 2 Diabetes,” and Mounjaro’s site says Mounjaro “is a prescription medicine for adults and children 10 years of age and older with type 2 diabetes.” An affiliate page that sells either one as a weight-loss product makes a claim the label doesn’t. If a brand lists Ozempic on its menu, promote the program and let the provider decide the medication.
Compounded semaglutide and tirzepatide
Compounded semaglutide and tirzepatide are what most brands with a public GLP-1 affiliate rate card sell (see the commissions guide linked above), and they carry the strictest claim rules. FDA’s February 6, 2026 statement says companies cannot claim compounded products are “generic versions or the same as drugs approved by FDA,” that they “use the same active ingredient as the FDA-approved drugs,” or that they are “clinically proven to produce results for the patient.” HealthRX, which pays affiliates on compounded plans, puts this on its own affiliate page: “Wegovy® and Ozempic® are exclusively manufactured and distributed by Novo Nordisk®.”
The background on how compounding works and where FDA stands is in our compounded GLP-1 guide.
How GLP-1 affiliate payouts differ by drug
GLP-1 affiliate payouts often change with the medication, and not always in the same direction. Three brand-published examples, checked November 1, 2026:
| Program | Semaglutide | Tirzepatide | Paid on |
|---|---|---|---|
| HealthRX | $115 / $210 / $325 (3 / 6 / 12-month plans) | $165 / $320 / $540 | New customer’s first order; “Monthly plans do not commission.” |
| FindMyDirectDoctor (Awin) | $100 fixed, injection or oral | $150 fixed | The first medication payment; $25 on orders with a discount code |
| Good Girl Rx | $150 standard per verified paid referral | “Tirzepatide referrals are paid at a flat $75.” | A new customer’s first paid, doctor-approved order |
Two of the three pay more on tirzepatide, and one pays half. A percentage program such as BiltRx (“a generous 20% commission”) pays more on whichever plan costs more. Before you build a page around one drug, find out:
- whether the payout follows the drug the visitor picks or the plan length
- what happens to your commission when the provider prescribes a different drug than your page named
- whether branded and compounded orders on the same brand pay the same rate
Traffic and claim rules for GLP-1 drug offers
GLP-1 drug offers accept most content and search traffic, with conditions set by the drug type and the ad platform. The table covers the common sources.
| Traffic source | Status | Why |
|---|---|---|
| SEO and comparison content | Allowed | Name the program and the brand’s price; no “same as Wegovy” lines on compounded offers |
| Email and newsletters | Allowed with conditions | Brand-approved claims only; disclose the paid relationship |
| Coupon and deal sites | Varies by program | FindMyDirectDoctor’s Awin terms say “Coupon and deal sites not accepted” and pay $25 on discount-code orders; check each program’s terms |
| Meta ads naming a prescription drug | Allowed with conditions, often brand only | Meta requires telehealth providers to be “actively certified with LegitScript,” and Rx advertisers to “Obtain authorization from Meta”; some programs ban it outright, as HealthRX bans affiliates from Rx ads “on Google or Meta” from “your own ad accounts” |
| Ozempic or Mounjaro for weight loss | Not allowed | Both labels are type 2 diabetes |
| Push and pop traffic | Not allowed | We don’t accept push or pop traffic on GLP-1 offers |
Our rules for publishers on GLP-1 drug offers:
- Sell the program. The provider decides the prescription. Your page sells access to that provider and the brand’s plan.
- Match the landing page. Don’t name a drug the landing page doesn’t sell, and don’t call a compounded product by a brand name.
- Make no results claims: no weight figures, no before-and-after, no trial numbers borrowed from Wegovy or Zepbound.
If you promote semaglutide, tirzepatide or branded GLP-1 offers today, send us your current GLP-1 payout. We’ll beat it. The terms are on our payout match page, and how our program works is on our page about GLP-1 affiliate program.
FAQ
Does Novo Nordisk have an affiliate program for Wegovy or Ozempic?
We found no public affiliate program on Novo Nordisk’s sites as of November 1, 2026. Novo sells Wegovy and Ozempic through NovoCare Pharmacy and lists independent telehealth providers. Affiliates earn through those providers’ programs.
Does Eli Lilly have an affiliate program for Zepbound or Foundayo?
We found no public affiliate program on Lilly’s sites as of November 1, 2026. LillyDirect sells Zepbound and Foundayo, and Lilly’s telehealth list says “Lilly does not endorse or recommend these health care providers.”
What is a semaglutide affiliate program?
A semaglutide affiliate program is a telehealth brand’s program that pays you when a visitor you send buys a weight-loss plan where a licensed provider may prescribe semaglutide, branded or compounded. The brand, not Novo Nordisk, sets the payout.
Can I promote the Wegovy pill as an affiliate?
Yes, through a telehealth brand that offers it. Name the pill only if the landing page sells it, and quote the brand’s price rather than NovoCare’s.
Sources
- NovoCare Pharmacy, home delivery page (self-pay prices and footnotes) · accessed
- NovoCare, Find care (telehealth providers) · accessed
- LillyDirect, homepage · accessed
- LillyDirect, Zepbound (self-pay prices) · accessed
- LillyDirect, Foundayo (self-pay prices) · accessed
- Lilly, Telehealth options for obesity · accessed
- Novo Nordisk, Wegovy pill approved in the US as first oral GLP-1 for weight management (December 22, 2025) · accessed
- Wegovy.com, indication · accessed
- Ozempic.com, homepage · accessed
- Mounjaro, homepage (indication) · accessed
- HealthRX, Affiliates (rate card) · accessed
- Awin, FindMyDirectDoctor merchant profile · accessed
- Good Girl Rx, Affiliate Program · accessed
- BiltRx, Affiliate Program · accessed
- WeightWatchers, Affiliate Program · accessed
- Lilly, Foundayo (orforglipron) now available in the U.S. (April 9, 2026; FDA approval April 1, 2026) · accessed
- Henry Meds, Programs (compounded oral tablets) · accessed
- FDA, FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs (February 6, 2026) · accessed
- Meta Transparency Center, Drugs and pharmaceuticals · accessed